Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy

BACKGROUND: Adjuvant chemotherapy after the resection of stage IB-IIIA non-small cell lung cancer (NSCLC) is now the standard of care based on large-scale phase III trials and a meta-analysis. However, chemotherapy has plateaued in terms of its efficacy, and the search for treatment prediction bioma...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:World J Surg Oncol
Glavni autori: Shimizu, Katsuhiko, Yukawa, Takuro, Okita, Riki, Saisho, Shinsuke, Maeda, Ai, Nojima, Yuji, Nakata, Masao
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4332968/
https://ncbi.nlm.nih.gov/pubmed/25888998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12957-014-0426-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items